首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1679341

吸入式生技藥品市場規模、佔有率、趨勢分析報告：按生技藥品、應用、劑型、分銷管道、地區、細分市場預測，2025-2030 年

Inhalable Biologics Market Size, Share & Trends Analysis Report By Biologics, By Application, By Dosage Form, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日期: 2025年02月27日 | 出版商:

Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

吸入生技藥品市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球吸入式生技藥品市場規模預計到2030年將達到100.6億美元，2025年至2030年期間的複合年成長率為17.6%。

該市場的成長動力包括呼吸系統疾病的日益普及、對非侵入性藥物輸送的需求不斷成長以及增強生物穩定性的配方技術的進步。該市場受益於患者對自我給藥的偏好、透過肺部輸送更快的藥物起效以及對吸入式單株抗體、胜肽和基於 RNAi 的療法的研究。監管支援和技術創新將進一步擴大市場機會。

氣喘、慢性阻塞性肺病和囊腫纖維化等呼吸系統疾病的高發生率仍是主要促進因素。根據 CDC 和 ACAAI 的數據，到 2023 年，氣喘將影響 7.7% 的美國（2,490 萬人），導致醫療保健使用量和成本大幅增加。吸入生技藥品可快速輸送到肺部，增強治療效果，同時最大限度地減少全身副作用。 Ocugen、Moderna、輝瑞-BioNTech 和阿斯特捷利康等公司正在透過吸入式疫苗和治療方法擴大其產品組合。例如，Ocugen 於 2025 年 1 月在其第一階段測試中獲得了 FDA 對其吸入式 COVID-19 疫苗 OCU500 的批准，而 MannKind Corporation 在第三階段測試取得積極結果後獲得了印度監管部門的核准，並繼續擴大 Afrezza 的市場。

市場管道依然活躍，吸入式生技藥品主要針對呼吸系統疾病、糖尿病、感染疾病和癌症。一項值得注意的創新是使用兩性離子聚合物功能化的脂質奈米顆粒 (LNP) 進行吸入式 mRNA 療法，該療法於 2024 年 11 月發表在《美國化學學會雜誌》上，並證明了穩定的霧化和有效的肺部輸送。

2024 年 12 月，繼美國和巴西之後，MannKind Corporation 和 Cipla Ltd. 獲得了印度 CDSCO核准，允許其在印度使用成人 Afrezza（人類胰島素）吸入粉劑。根據這項策略舉措，MannKind 將供應產品，而 Cipla 將負責行銷和分銷，預計將於 2025 年下半年出貨。此次合作旨在加強 Afrezza 的全球影響力，尤其是在印度，那裡有超過 7,400 萬成年人患有糖尿病。 Afrezza 是一種非注射型速效胰島素，可快速吸收並在兩到三小時內起效，滿足了患者對創新、以患者為中心的糖尿病管理解決方案的偏好。 Cipla 廣泛的分銷網路旨在增強印度各地患者的治療機會並改善其治療效果。安全措施包括對患有慢性肺病的患者要謹慎，因為有支氣管痙攣的風險。

作為其在吸入式生技藥品領域管線進展的一部分，Ab Initio Pharma 已作為銀牌贊助商加入第 35 屆肺部藥物輸送 (DDL) 會議，該會議將於 2024 年 12 月 11 日至 13 日在愛丁堡舉行。此次加入標誌著一項策略性舉措，旨在突出藥物輸送解決方案，包括小分子、胜肽、寡核苷酸和基於 RNA 的療法。會議的主要特色包括關於鼻腔 mRNA 遞送的演示和關於吸入寡核苷酸的海報，重點介紹非侵入性治療方法的創新。

這些舉措凸顯了該公司致力於透過戰略夥伴關係、監管部門核准和專注於慢性病和感染疾病的管道創新來擴大吸入治療方法的可及性並加強其全球市場地位。

吸入生技藥品市場報告重點

按類型分類，肽蛋白領域由於其廣泛的治療應用、更高的穩定性和高效的肺部吸收，在 2024 年佔據市場領先地位，收益佔有率最大，為 29.85%。
預測期內，RNAi 藥物領域預計將以強勁的複合年成長率成長。
根據應用，糖尿病領域在 2024 年佔據了最大的市場收益佔有率。然而，呼吸系統疾病預計在預測期內將以快速的複合年成長率成長。
根據劑型，乾粉吸入器在 2024 年佔據最大的市場收益佔有率。然而，霧化器部分預計在預測期內將經歷最快的複合年成長率。
按分銷管道分類，醫院藥房部門在 2024 年佔據最大的市場收益佔有率。
2024年12月，Cipla於2024年12月11日獲得CDSCO核准，在印度獨家分銷和銷售由MannKind Corporation開發的Afrezza（一種吸入式胰島素製劑）。 Afrezza 是一種用於治療第 1 型和第 2 型糖尿病的速效胰島素製劑，是一種非注射替代品，可快速吸收並在兩到三小時內起效。 Cipla 旨在利用其分銷網路來提高糖尿病管理的可及性，從而改善印度各地患者的治療效果。

2024 年及 2030 年區域市場佔有率分析
區域市場儀表板
2018-2030 年市場規模及預測趨勢分析
北美洲
- 按國家/地區，2018 年至 2030 年
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 丹麥
- 瑞典
- 挪威
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 泰國
拉丁美洲
- 巴西
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第9章競爭格局

參與者概述
企業市場分析
公司分類
戰略地圖
公司簡介/上市公司
- Kamada Pharmaceuticals
- MannKind Corporation
- Ab Initio Pharma
- Ocugen, Inc.
- CanSino Biologics
- AstraZeneca

簡介目錄圖表

Product Code: GVR-4-68040-530-0

Inhalable Biologics Market Growth & Trends:

The global inhalable biologics market size is anticipated to reach USD 10.06 billion by 2030 and is projected to grow at a CAGR of 17.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growth drivers include the increasing prevalence of respiratory diseases, rising demand for non-invasive drug delivery, and advancements in formulation technologies enhancing biologic stability. The market benefits from patient preference for self-administration, faster drug onset through pulmonary delivery, and research on inhalable monoclonal antibodies, peptides, and RNAi-based therapeutics. Regulatory support and technological innovations further expand market opportunities.

The high prevalence of respiratory conditions, including asthma, COPD, and cystic fibrosis, remains a key growth driver. According to the CDC and ACAAI, asthma affected 7.7% of Americans (24.9 million) in 2023, leading to significant healthcare utilization and costs. Inhalable biologics offer targeted lung delivery with rapid onset, enhancing treatment efficacy while minimizing systemic side effects. Companies such as Ocugen, Moderna, Pfizer-BioNTech, and AstraZeneca are expanding their portfolios through inhaled vaccines and therapeutics. For instance, Ocugen received FDA clearance in January 2025 for a Phase 1 trial of OCU500, an inhaled COVID-19 vaccine, while MannKind Corporation continues to expand Afrezza's reach, with Indian regulatory approval following positive Phase 3 trial results.

The market pipeline remains active, with inhalable biologics targeting respiratory diseases, diabetes, infectious diseases, and oncology. A notable innovation includes inhalable mRNA therapeutics using lipid nanoparticles (LNPs) functionalized with zwitterionic polymers, as published in the Journal of the American Chemical Society in November 2024, demonstrating stable nebulization and effective pulmonary delivery.

In December 2024, MannKind Corporation and Cipla Ltd. secured CDSCO approval for Afrezza (insulin human) Inhalation Powder for adults in India, following prior approvals in the U.S. and Brazil. Under this strategic initiative, MannKind will supply the product while Cipla manages marketing and distribution, with shipments expected by late 2025. The move aims to strengthen Afrezza's global presence, particularly in India, where over 74 million adults are affected by diabetes. Afrezza offers a non-injectable, rapid-acting insulin alternative, with quick absorption and a 2-3 hour effect, addressing patient preferences for innovative and patient-centric diabetes management solutions. Cipla's extensive distribution network is positioned to enhance access and improve patient outcomes across India. Safety measures include precautions for patients with chronic lung diseases due to the risk of bronchospasm.

As part of pipeline advancements in inhalable biologics, Ab Initio Pharma participated as a Silver Sponsor at the 35th Drug Delivery to the Lungs (DDL) Conference from December 11-13, 2024, in Edinburgh. This engagement represents a strategic initiative to highlight its drug delivery solutions, including small molecules, peptides, oligonucleotides, and RNA-based therapies. Key conference features include a presentation on intranasal mRNA delivery and a poster on inhaled oligonucleotides, emphasizing innovation in non-invasive treatment modalities.

These initiatives underscore a growing emphasis on expanding access to inhalable therapies and strengthening global market positions through strategic partnerships, regulatory approvals, and pipeline innovations focused on chronic and infectious diseases.

Inhalable Biologics Market Report Highlights:

Based on type, the peptides and proteins segment led the market with the largest revenue share of 29.85% in 2024, due to their broad therapeutic applications, stability improvements, and efficient pulmonary absorption.
The RNAi-based therapeutics segment is projected to grow at a robust CAGR over the forecast period.
Based on applications, the diabetes segment accounted with the largest market revenue share in 2024. However, respiratory diseases are expected to grow at a rapid CAGR over the forecast period.
Based on dosage form, the dry powder inhalers segment accounted for the largest market revenue share in 2024, aided by approved products in the segment. However, the nebulizers segment is expected to witness at the fastest CAGR over the forecast period.
Based on the distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024.
In December 2024, Cipla received CDSCO approval on December 11, 2024, to exclusively distribute and market Afrezza (inhaled insulin) in India, developed by MannKind Corporation. Afrezza is a rapid-acting insulin for type 1 and type 2 diabetes, offering a non-injectable alternative with quick absorption and a 2-3 hour effect. Cipla aims to enhance diabetes management accessibility, leveraging its distribution network to improve patient outcomes across India.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. Dosage Form
- 1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Inhalable Biologics Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
3.4. Pipeline Analysis
- 3.4.1. List of Drug Candidates (Phase 1 to Phase 3)
- 3.4.2. Potential Drugs to be Commercialized in the Forecast Period
- 3.4.3. Phase 3 Drug Forecast
3.5. Case Study Analysis

Chapter 4. Inhalable Biologics Market: Type Business Analysis

4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Peptides and Proteins
- 4.4.1. Peptides and Proteins Market, 2018 - 2030 (USD Million)
4.5. Vaccines
- 4.5.1. Vaccines Market, 2018 - 2030 (USD Million)
4.6. Monoclonal Antibodies
- 4.6.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
4.7. RNAi-based Therapeutics
- 4.7.1. RNAi-based Therapeutics Market, 2018 - 2030 (USD Million)
4.8. Others
- 4.8.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 5. Inhalable Biologics Market: Application Business Analysis

5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Respiratory Diseases
- 5.4.1. Respiratory Diseases Market, 2018 - 2030 (USD Million)
- 5.4.2. COPD
  - 5.4.2.1. COPD Market, 2018 - 2030 (USD Million)
- 5.4.3. Asthma
  - 5.4.3.1. Asthma Market, 2018 - 2030 (USD Million)
- 5.4.4. Cystic Forbis
  - 5.4.4.1. Cystic Forbis Market, 2018 - 2030 (USD Million)
- 5.4.5. Covid-19
  - 5.4.5.1. Covid-19 Market, 2018 - 2030 (USD Million)
- 5.4.6. Others
  - 5.4.6.1. Others Market, 2018 - 2030 (USD Million)
5.5. Diabetes
- 5.5.1. Diabetes Market, 2018 - 2030 (USD Million)
5.6. Cancer
- 5.6.1. Cancer Market, 2018 - 2030 (USD Million)
5.7. Others
- 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Inhalable Biologics Market: Dosage Form Business Analysis

6.1. Dosage Form Market Share, 2024 & 2030
6.2. Dosage Form Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
6.4. Dry Powder Inhalers
- 6.4.1. Dry Powder Inhalers Market, 2018 - 2030 (USD Million)
6.5. Metered Dose Inhalers
- 6.5.1. Metered Dose Inhalers Market, 2018 - 2030 (USD Million)
6.6. Nebulizers
- 6.6.1. Nebulizers Market, 2018 - 2030 (USD Million)
6.7. Others
- 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Inhalable Biologics Market: Dosage Form Business Analysis

7.1. Dosage Form Market Share, 2024 & 2030
7.2. Dosage Form Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
7.6. Online Pharmacies
- 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Inhalable Biologics Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
- 8.4.1. North America Inhalable Biologics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Target Disease Prevalence
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Reimbursement Framework
  - 8.4.2.5. U.S. Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Reimbursement Framework
  - 8.4.3.5. U.S. Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Framework
  - 8.4.4.5. Mexico Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
- 8.5.1. Europe Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Target Disease Prevalence
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Reimbursement Framework
  - 8.5.2.5. UK Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Framework
  - 8.5.3.5. Germany Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Target Disease Prevalence
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. Reimbursement Framework
  - 8.5.4.5. France Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Target Disease Prevalence
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Reimbursement Framework
  - 8.5.5.5. Italy Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Target Disease Prevalence
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Reimbursement Framework
  - 8.5.6.5. Spain Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Target Disease Prevalence
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Reimbursement Framework
  - 8.5.7.5. Denmark Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Target Disease Prevalence
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Reimbursement Framework
  - 8.5.8.5. Sweden Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Target Disease Prevalence
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Reimbursement Framework
  - 8.5.9.5. Norway Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Target Disease Prevalence
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Reimbursement Framework
  - 8.6.2.5. Japan Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Target Disease Prevalence
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Reimbursement Framework
  - 8.6.3.5. China Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Target Disease Prevalence
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Reimbursement Framework
  - 8.6.4.5. India Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Target Disease Prevalence
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Reimbursement Framework
  - 8.6.5.5. Australia Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Target Disease Prevalence
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. Reimbursement Framework
  - 8.6.6.5. South Korea Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Target Disease Prevalence
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Reimbursement Framework
  - 8.6.7.5. Thailand Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Target Disease Prevalence
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Reimbursement Framework
  - 8.7.2.5. Brazil Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Target Disease Prevalence
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Reimbursement Framework
  - 8.7.3.5. Argentina Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Inhalable Biologics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Target Disease Prevalence
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. Reimbursement Framework
  - 8.8.2.5. South Africa Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Target Disease Prevalence
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Reimbursement Framework
  - 8.8.3.5. Saudi Arabia Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Target Disease Prevalence
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. Reimbursement Framework
  - 8.8.4.5. UAE Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Target Disease Prevalence
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Reimbursement Framework
  - 8.8.5.5. Kuwait Inhalable Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
- 9.5.1. Kamada Pharmaceuticals
  - 9.5.1.1. Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. MannKind Corporation
  - 9.5.2.1. Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. Ab Initio Pharma
  - 9.5.3.1. Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. Ocugen, Inc.
  - 9.5.4.1. Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. CanSino Biologics
  - 9.5.5.1. Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. AstraZeneca
  - 9.5.6.1. Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Strategic Initiatives

簡介目錄圖表

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global inhalable biologics market, by region, 2018 - 2030 (USD Million)
Table 4 Global inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 5 Global inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 6 Global inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 7 Global inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 8 North America inhalable biologics market, by country, 2018 - 2030 (USD Million)
Table 9 North America inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 10 North America inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 11 North America inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 12 North America inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 13 U.S. inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 14 U.S. Inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 15 U.S. inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 16 U.S. inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 17 Canada inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 18 Canada inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 19 Canada inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 20 Canada inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 21 Mexico inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 22 Mexico inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 23 Mexico inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 24 Mexico inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Europe inhalable biologics market, by country, 2018 - 2030 (USD Million)
Table 26 Europe inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 27 Europe inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 28 Europe inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 29 Europe inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 30 UK inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 31 UK Inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 32 UK inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 33 UK inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Germany inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 35 Germany inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 36 Germany inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 37 Germany inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 38 France inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 39 France Inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 40 France inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 41 France inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 42 Italy inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 43 Italy inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 44 Italy inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 45 Italy inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 46 Spain inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 47 Spain inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 48 Spain inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 49 Spain inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 Norway inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 51 Norway Inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 52 Norway inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 53 Norway inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 54 Denmark inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 55 Denmark inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 56 Denmark inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 57 Denmark inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 58 Sweden inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 59 Sweden inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 60 Sweden inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 61 Sweden inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Asia Pacific inhalable biologics market, by country, 2018 - 2030 (USD Million)
Table 63 Asia Pacific inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 64 Asia Pacific inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 65 Asia Pacific inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 66 Asia Pacific inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 67 Japan inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 68 Japan inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 69 Japan inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 70 Japan inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 71 China inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 72 China inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 73 China inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 74 China inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 India inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 76 India inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 77 India inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 78 India inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 79 Australia inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 80 Australia inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 81 Australia inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 82 Australia inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 83 South Korea inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 84 South Korea inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 85 South Korea inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 86 South Korea inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 87 Thailand inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 88 Thailand inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 89 Thailand inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 90 Thailand inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 91 Latin America inhalable biologics market, by country, 2018 - 2030 (USD Million)
Table 92 Latin America inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 93 Latin America inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 94 Latin America inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 95 Latin America inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 96 Brazil inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 97 Brazil inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 98 Brazil inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 99 Brazil inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 100 Argentina inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 101 Argentina inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 102 Argentina inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 103 Argentina inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Inhalable biologics market, by country, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 108 Middle East & Africa inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 109 South Africa inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 110 South Africa inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 111 South Africa inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 112 South Africa inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 117 UAE inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 118 UAE inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 119 UAE inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 120 UAE inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)
Table 121 Kuwait inhalable biologics market, by type, 2018 - 2030 (USD Million)
Table 122 Kuwait inhalable biologics market, by application, 2018 - 2030 (USD Million)
Table 123 Kuwait inhalable biologics market, by dosage form, 2018 - 2030 (USD Million)
Table 124 Kuwait inhalable biologics market, by distribution channel, 2018 - 2030 (USD Million)